Articles tagged with Stem Cell Therapy
Researchers have developed a drug-inducible system to generate human induced pluripotent stem (iPS) cells with high efficiency. The new method requires less time than previous approaches and shows promise for development of cell therapies.
Researchers have developed a novel imaging approach using fluorocarbon labeling to visualize cell populations of interest in living bodies. This technology enables non-invasive location, tracking, and counting of specific immune cells, aiding cancer research and treatment.
The University of Georgia has been awarded a $9.2 million grant to explore the molecular underpinnings of human embryonic stem cell differentiation, aiming to identify genetic and protein modification patterns that accompany this process.
Researchers at the University of Florida have identified a molecular signature based on gene expression that can predict the development of acute graft-versus-host disease (GVHD) in patients receiving liver stem cell transplants. This could lead to better biomarkers for determining patient risk and improving treatment outcomes.
Researchers found that transplanted bone marrow stromal cells can differentiate into liver cells and may be used for cell replacement therapy. The study also suggests that these cells are not the origin of liver cancer in mice.
A study led by Beth Israel Deaconess Medical Center finds that a tumor suppressor protein called PML enables leukemia-initiating cells to maintain quiescence, making them resistant to conventional therapies. Inhibiting PML with an arsenic-based agent successfully treats chronic myeloid leukemia when combined with chemotherapy.
The UCI Sue and Bill Gross Stem Cell Research Center will house up to 26 researchers, a master's program in biotechnology, and programs educating patients and the public. The facility is expected to advance stem cell therapies for treating spinal cord injuries and other diseases.
A new study by UC Davis researchers provides evidence that methods using human bone marrow-derived stem cells to deliver gene therapy do not cause the development of tumors or leukemia. The study tested the safety of gene transfer into bone marrow stem cells in over 600 mice, with none developing leukemia or solid tumors.
StemCyte's move to New Jersey is driven by collaboration with Rutgers and a desire for proximity to groundbreaking research. The company will house its executive management and therapeutics team at the new office, which will support its northeast US operations.
Researchers are exploring the potential of generating insulin-producing cells using adult stem cells to treat type 1 diabetes. The partnership aims to restore normal blood sugar levels through autologous cell transplantation, eliminating the need for immunosuppressive agents.
Researchers are exploring optimal dosage and timing for stem cell therapy in adults with strokes and newborns with ischemic injuries. Pilot studies indicate a 25% improvement in recovery, leading to plans for clinical trials within two years.
Researchers found that human mesenchymal stem cells (hMSCs) and bone marrow stromal cells (BMSCs) can migrate to damaged brain tissue after a stroke, improving neural function. The transplanted cells may also enhance tissue repair and functional recovery.
Researchers have made significant progress in cardiac stem cell therapy, exploring novel delivery methods and strategies to improve cell survival. These advancements aim to overcome the challenges of poor vascular supply and inflammation after a heart attack, paving the way for more effective treatments.
Researchers have developed four unique human parthenogenetic stem cell lines that are HLA-homozygous, reducing the risk of provoking an immune reaction. These lines can serve as a renewable source of transplantable cells for treating genetic and degenerative diseases.
UCI researchers have found a novel method to sort stem cells based on their electric charges, which could expedite therapies for conditions like Alzheimer's and Parkinson's diseases. The technique uses electrodes on a tiny glass slide and has the potential to be more cost-effective and quicker than current methods.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
A recent study by MIT scientists suggests that adult stem cells produced in the brain can only make limited connections, making it challenging to use them for replacement therapy. The research calls into question the potential of using adult stem cells to repair damaged brain tissue and replace lost neurons.
Two studies found a significant increase in five- and ten-year survival rates for MM patients over the past decade, with younger patients showing the most dramatic improvement. Novel therapies have been credited with this trend, particularly among younger patients.
Researchers at Cedars-Sinai Medical Center have developed a novel gene delivery system that can sustain therapeutic expression in the central nervous system for up to 1 year. This innovative approach uses an adenoviral vector called HC-Adv, which is invisible to the immune system and renders previously used vectors ineffective.
Meis1 is required for maintaining leukemia stem cell properties in MLL leukemia, including self-renewal and differentiation arrest. The study provides new insights into the genetic underpinnings of MLL leukemogenesis.
The study found that aging stem cells in fruit flies experienced a decline in growth factor unpaired (upd), leading to reduced stem cell numbers. Artificially increasing upd levels delayed the loss of germline stem cells, suggesting that the niche's molecular signals govern stem cell behavior.
Scientists have discovered a new approach to treat Huntington's disease using stem-cell therapy, which created thousands of new medium spiny neurons in mice. The treatment resulted in improved health and lifespan for the treated mice.
Researchers found that certain cancer treatments can increase the expression of Nanog and BMI1 stem cell markers in cancer cells, allowing them to survive treatment and potentially leading to tumor growth. Understanding these pathways could lead to the development of new therapeutic targets.
Researchers at Children's Hospital of Pittsburgh have identified a unique population of adult stem cells derived from human muscle tissue that can be used to treat muscle injuries and diseases. The myoendothelial cells are easily isolated, proliferate rapidly, and can differentiate into muscle, bone, and cartilage cells.
The HIV/AIDS virus affects adult neural progenitor cells in the brain, preventing them from dividing and contributing to neurodegeneration. The protein gp120 causes both brain injury and prevents its repair, highlighting a potential target for new therapies.
Testicular cancer patients with metastatic disease can be cured with high-dose chemotherapy and a stem cell transplant, as shown in an Indiana University School of Medicine report. The treatment, which involves carboplatin chemotherapy at five times the standard dosage, has a success rate of over 90%.
The Revlimid data presented at ASCO demonstrates a greater one-year survival advantage for patients receiving low dose dexamethasone compared to those receiving the standard high dose of the steroid. In all age ranges, patients benefit from Revlimid with the low dose dexamethasone, showing improved survival rates.
The Friedlander lab will work with six other laboratory groups to conduct pre-clinical work on adult stem cells, aiming to develop a new approach to treating retinal diseases. The therapy targets abnormal blood vessel formation, which is a leading cause of vision loss in Americans.
A recent study published in Cell Stem Cell found that nearly half of couples who underwent in vitro fertilization (IVF) chose to donate their surplus embryos for stem cell research. The key factor was a clear explanation of the options, which helped couples navigate the legal situation and address concerns about donation.
Dr. Evan Snyder's study demonstrates human neural stem cells slow Sandhoff disease progression in mice, offering promise for brain repair therapies for special-needs children. The research lays groundwork for potential therapies for other complex childhood brain disorders.
A Phase 1 trial of mesenchymal stem cells (MSCs) has shown significant improvements in heart function and reduced side effects in patients with acute myocardial infarction (MI). The study, led by Joshua Hare, M.D., found that MSC-treated patients had lower rates of cardiac arrhythmias and improved heart, lung, and global function.
Researchers used human embryonic stem cells to treat a degenerative disease in mice, demonstrating the first successful use of hESCs in a diseased brain. The treatment not only replaced damaged nerve cells but also boosted the brain's supply of an enzyme and reduced inflammation.
Researchers at the University of Pennsylvania have successfully used uniparental embryonic stem cells to repopulate a damaged organ with healthy cells in adult mice. This breakthrough could provide a less controversial alternative to traditional embryonic stem cell therapy, and may offer therapeutic benefits for both males and females.
A sugar molecule called SSEA-4 has been found on the surface of adult stem cells in bone marrow, which give rise to fat, cartilage, and bone. This discovery may help isolate and purify these cells for use in therapies aimed at bone healing, tendon repair, and cartilage regeneration.
Researchers have made breakthroughs in transforming adult stem cells into various tissue types, such as blood vessel cells, nerve-like cells, and muscle-like cells. These advancements hold promise for treating conditions like Parkinson's disease, diabetes, and spinal cord injuries.
Regenerative medicine holds promise for affordable treatments and offsetting donor shortages, particularly for diabetes, heart disease, and infectious diseases. The study prioritizes 10 applications, including novel insulin replacement methods, regenerating failed heart muscle, and engineered immune cells.
The Tri-Institutional Stem Cell Initiative has approved $6.7 million in funding for 17 stem cell research projects, exploring basic biology and therapeutic potential of human and model organism-derived stem cells. The grants support collaborative research across three institutions, including Memorial Sloan-Kettering Cancer Center.
Researchers developed an effective treatment using embryonic stem cells to restore motor function in paralyzed rats. GDNF was found to be a focal attractive cue for transplanted axons, facilitating the establishment of neuromuscular junctions and resulting in noticeable recovery.
The study found that the average time to disease progression was approximately eight months for patients taking dexamethasone alone, while those on the Thal/Dex regimen had an average progression time exceeding 17 months. Researchers also reported more frequent side effects with the combination therapy.
Researchers found that rituximab reduced the severity of chronic GVHD in 70% of study participants, with nearly three-fourths experiencing complete remissions. The therapy also enabled patients to reduce corticosteroid use by over 50%.
Researchers have discovered two new sources of stem cells with high cardiomyogenic potential, derived from menstrual blood and umbilical cord blood. These findings suggest that these cells may be able to repair or replace damaged cardiac muscle, offering a promising treatment option for heart dysfunctions.
A recent study found that stem cell mobilization therapy does not improve left ventricular recovery in patients with acute myocardial infarction. Despite significant mobilization of bone marrow stem cells, treatment did not alter infarct size or risk of restenosis or major adverse cardiac events.
A radical proposal suggests that California's CIRM could accelerate the development of stem cell therapies by implementing a patent pool and a shared prize system. This approach aims to stimulate innovation, make treatments more affordable, and establish a new medical innovation model for the 21st century.
The sympathetic nervous system plays a crucial role in regulating hematopoietic stem cell mobilization. Researchers found that defects in the transmission of signals via this system can stall stem cell movement. Drugs that stimulate the sympathetic nervous system restored stem cell movement in mice with impaired ability to respond to n...
Cedars-Sinai researchers have developed a new delivery system that can effectively regulate therapeutic gene expression, overcoming obstacles in bringing genetic therapies to humans. The system allows for the flexibility to turn gene expression on or off, even in the presence of an immune response, making it a critical tool for treatin...
Researchers estimated that 150 blood group compatible donors, 100 O donors, or ten highly selected donors could provide maximum benefit for HLA matching. The study aims to establish a hESC bank with sufficient HLA diversity for the UK population.
The NHLBI-funded program aims to translate knowledge into clinical practice for treating heart, lung, and blood diseases. It focuses on repairing damaged heart muscle, reducing immune complications, and enhancing adult stem cell interactions.
Researchers at UCI identified a protein called prokineticin 2 (PK2) that directs new neurons created from adult stem cells to specific brain regions. This discovery could lead to targeted therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as stroke and other brain injuries.
A new study reveals how the GDF11 protein controls retinal-cell differentiation during development, making it an attractive therapeutic target. By manipulating this process, researchers may be able to harness the power of existing stem cells in the retina to replace damaged or diseased cells and potentially cure visual disorders.
Researchers used SPECT imaging to evaluate the effectiveness of stem cell therapy in patients with coronary heart disease. The study found that stem cells improved damaged heart function, surpassing improvements from increased blood flow to the affected area.
A study of 11 patients with non-Hodgkin's lymphoma who have failed standard chemotherapy found that Zevalin was effective in inducing partial and complete responses in three patients. The treatment was well-tolerated, with side effects including thrombocytopenia and neutropenia.
Researchers at UCLA's new $20 million Institute for Stem Cell Biology and Medicine are exploring various approaches to combat HIV, cancer and neurological disorders. The institution aims to harness the power of embryonic and adult stem cells to develop revolutionary new treatments.
Researchers from the Forsyth Institute and University of Texas Health Science Center at San Antonio describe successful experiments in bioengineering mineralized tissues, including periodontal tissues and replacement tooth phenotypes. This breakthrough is supported by the National Institute of Dental and Craniofacial Research.
Researchers have developed a new way to culture human embryonic stem cells without using animal-derived materials, reducing the risk of contamination with pathogens. This breakthrough could lead to safer and more effective stem cell therapies for treating various diseases.
The level of signal-joint TRECs (sjTRECs) in the blood appears to directly reflect the ability of the transplant recipient's thymus gland to process donated stem cells. High levels of sjTRECs indicate a successful reconstitution of the T cell population, improving patient outcomes.
A new study has provided proof of principle for a combined stem cell-gene therapy approach as a potential treatment for cystic fibrosis. The researchers were able to correct the CFTR gene defect using adult stem cells and ex vivo gene therapy, which may offer advantages in screening and long-term function.
Researchers transplanted BM-SP stem cells into mice with cardiomyopathy, but found that only 2 muscle fibers expressed restored sarcoglycan levels. The study suggests alternative approaches should be investigated for regenerative medicine.
Researchers identified a complete deficiency in the CD3 epsilon chain of the T cell receptor causing SCID, leading to normal B cells but no T cells. Early diagnosis via bone marrow stem cell transplantation can result in a survival rate as high as 97% for patients with this mutation.
Researchers at Mayo Clinic demonstrate the potential of embryonic stem cells to rebuild damaged heart tissue, improving contractile function and ventricular remodeling. The study found that stem cell-derived cardiomyocytes integrated into infarcted areas without adverse effects.
Researchers at the NIH will conduct a clinical study to assess the safety and efficacy of hematopoietic stem cell transplantation in treating severe forms of lupus. The study aims to create a new immune system that doesn't attack healthy cells, offering hope for patients with limited treatment options.